Given that DNAM-1 ligands are expressed in many solid tumor [79], this treatment approach proves effective not only for neuroblastoma but also for colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and other solid tumors exhibiting p53 dysfunction [80]. The gene discussed is CD226; the disease is neuroblastoma.